🤖 Biotech + AI

A match made in heaven [Image] AI has the potential revolutionize genomics and medicine. Scientists already use it to analyze and interpret large amounts of genetic data that seemed impossible a decade ago. AI could change the way we diagnose and treat disease, leading to more precise diagnoses and better treatment outcomes. Is it any wonder it’s been the hottest sector to trade in 2023? We all know that small biotech companies can catch fire with the smallest positive press release. So it seemed obvious that Avalon Globo Care Corp. (ALBT), a biotech trying to ride the AI trend, was the perfect promoter push to cover today. Avalon GloboCare Corp (NASDAQ: ALBT) - 1-month trading range: $1.98 - $3.87 - Typical average daily volume: ~211,00 - Float: 3.28 million Avalon’s Business Avalon is a clinical-stage biotechnology company and laboratory testing provider focused on developing innovative immune effector cell therapies. They work on creating new medicines that help the body’s immune system fight off diseases. Avalon handles everything from early research to creating medicine in a lab and testing it on people. Additionally, the company has a special team dedicated to testing for diseases and ensuring people are healthy. Last summer, the company’s QTY Code was featured in Chemical Reviews, a top-ranked peer-reviewed scientific journal. The “QTY Code” is a breakthrough technology that can turn difficult to work with water-insoluble transmembrane receptor proteins into water-soluble proteins, greatly enhancing the solubility of designer peptides and proteins, therefore expanding the repertoire of selected therapeutic targets against cancers and other diseases. They’re called ‘transmembrane’ because they span the entire cell’s membrane. These proteins are responsible for transmitting signals from outside to inside the cell. Water soluble proteins are charged and essentially grab onto bad stuff like cancer trying to cross into the cell, keeping it on the outer surface, where as insoluble let garbage flow in and out… Or at least this is my limited understanding and imagery of how this all works. The other business Avalon is excited about is its Laboratory Services. Avalon’s Laboratory Services include drug tests, genetics, and sexually transmitted diseases. They also test things like your thyroid, kidney, and liver function. The company plans to embark on a rollup acquisition strategy of small to medium size laboratories accretive to its strategy and complimentary to its membership interest in Lab Services. Financials The company only generates income from a commercial rental property it owns. However, it believes it will soon generate revenue through its membership interest in Laboratory Services in toxicology and wellness testing. Over the last twelve months, it has made $1.2 million in revenue. And while it’s far from profitable, the company’s financial position isn’t that bad. Avalon has $1.99 million in cash with total debt of $4.57 million. Its current ratio of 3.2x is a clear example of how financially sound the company is in the near term. However, its operating cash flow is -$7.0 million, and its levered cash flow is -$11.9 million. Management could be doing a better job. After all, -31.0% return on assets and -167.5% return on equity is pretty awful. On the bright side, its price-to-book ratio is notably lower than last year, 8.9x compared to 20.1x. On April 11th, the company released a statement that it reached an agreement with Qi Diagnostics to distribute KetoAir Breathalyzer exclusively and AI-enabled software in North America, South America, the U.K., and European Union. Anytime you mention AI in your headline, you’ll get traders excited. Promoter Activity I received a few emails from two different promoters on Avalon. The first promoter I’ll mention described Avalon as a biotech company and how it applies artificial intelligence protein design “QTY-Code” technology, which some think can accelerate the development of therapeutic monoclonal antibodies to treat cancer. It then directed me to a free report titled: This Low-Float AI-Enabled Biotech Just Gained a Foothold in the $315 Billion Diagnostics Market. It then gives seven reasons why the stock could trade higher: - Active chart - Upside potential (trading near lows) - Extremely low float - Strategic Investment - Roll-Up Synergies - FDA Approvals - Artificial Intelligence The company doesn’t have any FDA Approvals for the record. But the promoter is suggesting they might come in the future. Nonetheless, the promoter does highlight some exciting catalysts. For example, they do a great job of showing the reader the big opportunities in diagnostics and cell and gene therapies. Not to mention some mouth-watering headlines: [hHoTj-tCJtqy5dKGhJnIkDDlOQ6hdmKJRgwN0R5vWGTZ720xtM0BoQWCxvLIJjYdivw0Oxf0hQtBw8c5awiYC4gtdblAgArwXt81sUYXziW-OHuXTw3gI5ZX4fn0NHNCoxvSocovEfoIw1sw1uyOr7Q] It’s hard to believe, considering the only revenue the company currently receives is from rental income on its commercial property in New Jersey. But does it really matter? After all, trading is all about anticipating how others will react to the catalysts and price action. And one thing traders look at is its past price action. ALBT hit a high of $16.50 two years ago. And with the stock sitting at around $2, that means it has plenty of upside potential if it catches the right catalyst and sucks in enough stubborn short-sellers. The first promoter who directed readers to the report received $5,000 per subscriber who clicked the link to read the ALBT report. The length of the promotion was not disclosed. The second promoter highlighted the latest headline occurring on April 11th. Then begins to tout his previous winning picks. And then writes his five reasons why he thinks ALBT will trade higher… No. 1 - A Low Float Could Allow For Explosive Volatility (Daily) No. 2 - Multiple Oversold Technicals May Be Signaling HUGE Bounce/Reversal Potential No. 3 - Company Acquires 40% Interest In Premier Laboratory (Portfolio Continues To Grow) No. 4 - Game-Changing Patent News (Company Expands Robust IP Portfolio) No. 5 - Company's Fusion Gene Map Technology Seen As Major Breakthrough He then proceeds to go into deeper detail, explaining his five points. And you know what? The points sound compelling, and the message had some strong urgency behind it. The second promoter has been doing business with ALBT since August 2022 on and off. Their latest campaign runs from 4/10 to 4/13, in which they’ll receive $25,000. They also ran campaigns for ALBT from: - 4/03 to 4/7 for $40,000 - 3/22 to 3/24 for $25,000 - 2/27 to 2/28 for $17,000 Clearly, ALBT likes their work. They’ve paid them over $1 million since August of 2022. Straight to the Facts ALBT is brushing up against lows. It appears like promoters will have a few days to draw more attention to the company. If the company continues to put out new press releases, the stock does have the potential to run, given how beat up it is. But I would wait for a volume confirmation first. If it cracks over 1m shares traded daily it could see some good action. Always at your service, Baron Von Stocks TEXT "AWARE" TO 888-302-2141 For Instant Alerts Disclaimer: Always do your own research and consult with a licensed investment professional before investing. This communication is never to be used as the basis of making investment decisions and is for entertainment purposes only. At most, this communication should serve only as a starting point to do your own research and consult with a licensed professional regarding the companies profiled and discussed. Conduct your own research. This newsletter is not a recommendation nor an offer to buy or sell securities. This newsletter is owned by Red Oak Media Group LLC. Any wording found in this e-mail or disclaimer referencing to “I” or “we” or “our” or “AS” refers to Red Oak Media Group LLC. Our business model is to be financially compensated to market and promote small public companies. By reading our newsletter and our website you agree to the terms of our disclaimer, which are subject to change at any time. We are not registered or licensed in any jurisdiction whatsoever to provide investing advice or anything of an advisory or consultancy nature and are therefore unqualified to give investment recommendations. Companies with low prices per share are speculative and carry a high degree of risk, so only invest what you can afford to lose. By using our service, you agree not to hold our site, its editor’s, owners, or staff liable for any damages, financial or otherwise, that may occur due to any action you may take based on the information contained within our newsletters or on our website. We do not advise any reader to take any specific action. Losses can be larger than expected if the company experiences any problems with liquidity or wide spreads. Our website and newsletter are for entertainment purposes only. Never invest purely based on our alerts. Gains mentioned in our newsletter and on our website may be based on end-of-day or intraday data. This publication and its owners and affiliates may hold positions in the securities mentioned in our alerts, which we may sell at any time without notice to our subscribers, which may have a negative impact on share prices. Red Oak Media Group, 7940 Ann Arbor St Dexter MI USA 48130 To update contact information or unsubscribe from this list, please [click here](